Walleye Capital
BEAM icon

Walleye Capital’s Beam Therapeutics BEAM Stock Holding History

Walleye Capital’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,338
Closed -$37.1K – 4399
2025
Q4 		$37.1K Buy
+1,338
New +$34.1K ﹤0.01% 4148
2025
Q3 		– Sell
-894
Closed -$17.8K – 4503
2025
Q2 		$15.2K Buy
+894
New +$15.6K ﹤0.01% 4272
2025
Q1 		– Sell
-90,061
Closed -$2.23M – 4271
2024
Q4 		$2.23M Sell
90,061
-37,527
-29% -$958K 0.01% 1688
2024
Q3 		$3.13M Buy
127,588
+22,664
+22% +$586K 0.01% 1546
2024
Q2 		$2.46M Buy
104,924
+7,187
+7% +$177K ﹤0.01% 1912
2024
Q1 		$3.23M Buy
+97,737
New +$3.05M 0.01% 1640
2021
Q4 		– Sell
-4,829
Closed -$420 – 2101
2021
Q3 		$420 Buy
+4,829
New +$485K 0.01% 854

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Walleye Capital's BEAM Position: Q1 2026 in Review

Walleye Capital sold out of Beam Therapeutics (BEAM) in Q1 2026, closing a stake of 1,338 shares — an estimated $37.1K sold.

Walleye Capital first reported a position in BEAM in Q3 2021 and held it in 7 quarters. The position peaked at $3.23M in Q1 2024. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Walleye Capital reported no remaining Beam Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 1,338 Beam Therapeutics shares in Q1 2026, an estimated $37.1K.
  • Walleye Capital first reported a position in Beam Therapeutics in Q3 2021 and held it in 7 quarters.
  • Walleye Capital's Beam Therapeutics position peaked at $3.23M in Q1 2024.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.